Preferred term	N=30
Any immune-related adverse event	11 (37%)
Immune-related rash	6 (20)
Rash maculo-papular	4 (13)
Rash	2(7)
Dermatitis acneiform	1 (3)
Immune-related adrenal insufficiency	2 (7)
Immune-related hepatitis	2 (7)
Alanine aminotransferase increased	2 (7)
Aspartate aminotransferase increased	2 (7)
Immune-related pneumonitis	2 (7)
Interstitial lung disease	2 (7)
Immune-related thyroid disorders	2 (7)
Hypothyroidism	1 (3)
Thyroiditis	1 (3)
Other immune-related adverse events	1 (3)
Psoriasis	1 (3)

Table S1: Immune-related adverse events in patients treated with bintrafusp alfa

Data are n (%).